Show simple item record

dc.contributor.authorSánchez-Corral, Pilar
dc.contributor.authorPouw, Richard B.
dc.contributor.authorLópez Trascasa, Margarita 
dc.contributor.authorJózsi, Mihály
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)es_ES
dc.date.accessioned2018-09-26T13:42:58Z
dc.date.available2018-09-26T13:42:58Z
dc.date.issued2018-07-12
dc.identifier.citationFrontiers in Immunology 9.July (2018): Article 1607en_US
dc.identifier.issn664-322es_ES
dc.identifier.urihttp://hdl.handle.net/10486/685193
dc.description.abstractThe alternative pathway is a continuously active surveillance arm of the complement system, and it can also enhance complement activation initiated by the classical and the lectin pathways. Various membrane-bound and plasma regulatory proteins control the activation of the potentially deleterious complement system. Among the regulators, the plasma glycoprotein factor H (FH) is the main inhibitor of the alternative pathway and its powerful amplification loop. FH belongs to a protein family that also includes FH-like protein 1 and five factor H-related (FHR-1 to FHR-5) proteins. Genetic variants and abnormal rearrangements involving the FH protein family have been linked to numerous systemic and organ-specific diseases, including age-related macular degeneration, and the renal pathologies atypical hemolytic uremic syndrome, C3 glomerulopathies, and IgA nephropathy. This review covers the known and recently emerged ligands and interactions of the human FH family proteins associated with disease and discuss the very recent experimental data that suggest FH-antagonistic and complement-activating functions for the FHR proteinsen_US
dc.description.sponsorshipPS-C and ML-T are funded by grants PI16/00723 and PI15/00255 (Spanish Ministerio de Economía y Competitividad/ISCIII, and European Program FEDER) and B2017/BMD3673 (Complement II-CM network from the Comunidad de Madrid). MJ is supported by the National Research, Development and Innovation Fund of Hungary (NKFIA grants K 109055 and K 125219), the Kidneeds Foundation, Iowa, US, and by the Institutional Excellence Program of the Ministry of Human Capacities of Hungaryen_US
dc.format.extent19 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherFrontiers Mediaen_US
dc.relation.ispartofFrontiers in Immunologyen_US
dc.rights© 2018 Sánchez-Corral, Pouw, López-Trascasa and Józsi.es_ES
dc.subject.otherAge-related macular degenerationen_US
dc.subject.otherAtypical hemolytic uremic syndromeen_US
dc.subject.otherC3 glomerulopathyen_US
dc.subject.otherComplement activationen_US
dc.subject.otherComplement de-regulationen_US
dc.subject.otherFactor Hen_US
dc.subject.otherFactor H-related proteinen_US
dc.subject.otherOpsonizationen_US
dc.titleSelf-damage caused by dysregulation of the complement alternative pathway: Relevance of the factor H protein familyen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2018.01607es_ES
dc.identifier.doi10.3389/fimmu.2018.01607es_ES
dc.identifier.publicationfirstpage1607-1es_ES
dc.identifier.publicationissueJulyes_ES
dc.identifier.publicationlastpage1607-19es_ES
dc.identifier.publicationvolume9es_ES
dc.relation.projectIDGobierno de España. PI16/00723es_ES
dc.relation.projectIDGobierno de España. PI15/00255es_ES
dc.relation.projectIDComunidad de Madrid. B2017/BMD-3673/COMPLEMENTOII-CM//IMAS12es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record